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Purpose: To assess the clinical significance of WD40 repeat containing 62 (WDR62), a novel centrosome
abnormalities-associated gene, in ovarian cancer.
Materials and methods: In this study, WDR62 expression was assessed by western blot (6 ovarian cancer cell lines)
and immunohistochemistry (primary epithelial ovarian cancer clinical specimens), and clinical variables were
collected by retrospective chart review. Centrosome amplification was assessed by immunofluorescence staining in
ovarian cancer cell lines, and by immunohistochemistry staining in ovarian cancer samples.
Results: Six ovarian cancer cell lines exhibited significant WDR62 protein overexpression, and amplification of
centrosome. High-grade ovarian cancer specimens exhibited significantly stronger nuclear staining of WDR62 than
low-grade ovarian carcinoma specimens (80.4% vs 41.3%; P<0.012). High WDR62 expression was strongly associated
with supernumerary centrosome count in tumor cells (P < 0.001).
Conclusion: Our findings suggest that WDR62 overexpression is related to centrosome amplification in ovarian
cancer. It may be a novel useful differentiation biomarker and a potential therapy target for OC. Further assessment
of WDR62 expression is highly warranted in large, prospective studies.
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Epithelial ovarian cancer accounts for about 3% of total
cancer cases in women [1]. Ovarian cancer is a heteroge-
neous disease comprising distinct molecular and consists
of different histological types, which can be readily dif-
ferentiated by histological evaluation [2]. Different histo-
logical types of ovarian cancer seem to be regulated by
different pathogenic pathways.
As a candidate “hallmark” of cancer cells, centrosome
amplification (CA) has been frequently detected in a
growing list of human solid and haematological cancers,
as well as in pre-neoplastic lesions, including those of
the ovarian cancer [3,4]. Evidence suggests that CA is in-
volved in the transition from early to advanced stages of
carcinogenesis [5,6]. Deregulated centrosome duplication* Correspondence: yimingtao@hotmail.com
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reproduction in any medium, provided the oror maturation often results in increased centrosome size
and/or number, both of which show a positive and sig-
nificant correlation with aneuploidy and chromosomal
instability, thus contributing to cancer formation [7,8].
p53 is mutated in 90% of human cancers and has been
extensively correlated with aneuploidy, genomic instability,
and centrosome amplification [9,10]. Some centrosome-
associated proteins, such as Polo-like kinase 1 (PLK1),
Aurora-A and transforming acidic coiled-coil 1 (TACC1),
are documented to be important during the carcinogenesis
of OC [11]. Genes involved in spindle formation, centro-
some functions and mRNA transport along the micro-
tubule tracks should provide further information on
potential markers of docetaxel resistance [9]. In addition,
centrosome abnormalities occurred more frequently in
ovarian tumors with high grade and aggressive serous
subtype [4]. In light of these findings, identification of
centrosome abnormalities-associated proteins may reveal
novel biomarker or potential therapeutic targets of OC.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Association of WDR62 expression and clinical
characteristics
Cases WDR62 expression
Negative Positive p value
Age (years)
<60 34 14 (41.2%) 20 (58.8%) 0.157
≥60 51 13 (25.5%) 38 (74.5%)
Tumor size (cm)
<5 25 11 (44.0%) 14 (56.0%) 0.132
≥5 60 16 (26.7%) 44 (73.3%)
FIGO grade
Low 29 18 (62.1%) 11 (37.9%) 0.0004
High 46 9 (19.6%) 37 (80.4%)
FIGO stage
I 14 9 (64.3%) 5 (35.7%) 0.006
II 15 8 (53.3%) 7 (46.7%)
III 18 6 (33.3%) 12 (66.7%)
IV 28 4 (14.3%) 24 (85.7%)
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recently identified centrosome-associated gene, which
includes 32 exons, a single CpG island and poly-
adenylation signal. WDR62 is located at the human
chromosome 19q13.12 region and is synthetic to the re-
gions of CEBPG, GPI and UBA2 genes, which are all
verified to play important roles in DNA replication and
cell cycle progression [12,13]. WDR62 protein, which
mediates cellular signaling, transcription, mitotic and
apoptotic functions, has 15 WD40 repeat domains and
six potential mitogen-activated protein kinase (MAPK)
phosphorylation sites in the C-terminal. Notably, the
endogenous expression of WDR62 was strongly accu-
mulated at the spindle poles of dividing cells but not in
the nucleus when mitosis occurred, suggesting a critical
role of WDR62 in Hela cell proliferation [14]. Some re-
cent studies have also documented a critical role of
WDR62 in the proliferation of neuronal precursors, and
that mutation of the WDR62 gene will induce micro-
cephaly and dysplasia of human brain [15]. So far, to
our knowledge, the role of WDR62 in human malignan-
cies remains unknown.
Given the relationship between WDR62 and centrosome
amplification found in various cancers, it is intuitive to
hypothesize that WDR62 expression may critically medi-
ate the development of human ovarian cancer. Therefore,
we planned the present expanded investigation in ovarian
cancer for confirming our preliminary hypothesis.Materials and methods
Tissue specimens
In this study, a total of 85 human ovarian cancer samples
and 6 normal ovarian surface epithelium samples were
collected after surgery at Xiangya Hospital, Central South
University and Hunan Cancer Hospital, the Affiliated
Hospital of Xiangya Medical College from 2008 to 2010.
Among these 85 cases of OC, fresh specimens of high
grade ovarian cancer (n = 46) and low grade (n = 29) were
collected for Western blot analysis. In addition, tissues
were embedded in paraffin after fixation in 10% formalin
for histological diagnosis and immunohistochemistry
(IHC) analysis. Diagnosis was verified by a pathology re-
view at the institutional gynecologic oncology tumor
board. All of the patients were staged according to the
International Federation of Gynecology and Obstetrics
(FIGO) surgical staging system [16]. A gynecologic path-
ologist reviewed all of the pathology results for all of the
patients. The detail biomedical factors of these tumor
types are summarized in Table 1. Prior informed consent
was obtained from all recruited patients for ovarian car-
cinoma tissue specimens collection and the study proto-
cols were approved by the Ethics Committees of two
participating hospitals.Ovarian cancer cell lines
A2780 cell line was purchased from Institute of Biochem-
istry and Cell Biology, Chinese Academy of Sciences,
Shanghai, China. SKOV3, SW626 Caov-3, OVCAR3 and
OV-90cell lines were purchased from American Type
Culture Collection (ATCC, Manassas, VA). The cells were
cultured in low glucose Dulbecco’s Modified Eagle Media
(DMEM, GIBCO, Gaithersburg, MD) and supplemented
with 10% fetal bovine serum at 37°C under an atmosphere
of 95% air and 5% CO2.
Immunofluorescence (IF) staining
Immunofluorescences staining of centrosomes were
performed as previously described [17]. Briefly, treated
cells were rinsed with ice-cold phosphate- buffered saline
(PBS, pH 7.4) and were fixed with 3% paraformaldehyde.
The cells permeabilized with 0.1% Triton X-100 were in-
cubated with 5% bovine serum albumin in PBS containing
0.05% Tween-20 (PBS-T) for 30 min. After washing for
three times with PBS-T, phalloidin conjugated with FITC
was applied and the nuclei were counterstained by DAPI
(Invitrogen). Images were captured using microscope
(Nikon Eclipse TE2000-S, Tokyo, Japan) from three inde-
pendent experiments.
Western blot
Total protein was extracted and separated by SDS-
PAGE under reducing conditions and then transferred
onto PVDF membrane (Millipore, Bedford, MA). The
blocked membranes were then respectively incubated
with the primary antibodies at 4°C overnight followed by
HRP-conjugated secondary antibodies (KPL, Gaithersburg,
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alized using the enhanced chemiluminescence kit (Santa
Cruz Biotechnology, Santa Cruz, CA). The target signals
were quantified by BandScan software (Bio-Rad Labora-
tories, Hercules, CA) and defined as the ratio of target
protein relative to α-Tubulin.Immunohistochemistry
Tissue sections (4 μm thick) were prepared from paraffin-
embedded blocks. After antigen retrieval treatment in
10 mM citrate buffer (pH 6.0) at 95°C for 10 min, im-
munostaining was performed using the Envision System
with diaminobenzidine (Dako, Glostrup, Denmark). The
tissue sections were stained for WDR62 (dilution 1:400;
Sigma-Aldrich) detection using a mouse monoclonal
antibody, and a subsequently Streptavidin-Peroxidase sys-
tem (Zhongshan Goldenbridge Biotechnology, Beijing,
China). The negative controls for IHC were carried out
under the same experimental conditions by omitting the
primary antibody. The semiquantitation for intensity was
scored on a scale of 0, negative; 1, weak; 2, moderate and
3, strong [18]. We also evaluated the approximate propor-
tion of cells showing immunoreactive score (IS) (0, < 1%;
1, single to 5%; 2, 6-50%; 3, 51-75%; and 4,>75%) to give
information about the relative number of positive cells
within the specimen (frequency score) [19]. These two
kinds of scores were then multiplied to generate the IS for
each tissue specimen. Receive operating characteristic
(ROC) curve analysis was employed to assess cutoff score
for overexpression of WDR62. The score was selected as
the cut-off value, which was closest to the point of max-
imum Youden’s index (sensitivity + specificity-1) was used
for determination of optimal cut-off values of the diagnos-
tic tests. OC case designated as “negative expression” for
WDR62 was those with scores below or equal to the cut-
off value (IS < 2), while “positive expression” tumors were
those with scores above the value (IS ≥ 2).Figure 1 WDR62 expression in ovarian cancer cell lines.
(A) Whole cell lysates from multiple ovarian cancer cell lines were
subjected to Western blot using primary anti-WDR62 antibody.
(B) Cells in culture was exposed to anti-centrosome antibodies. After
secondary antibody-FITC (green), cells were exposed to 4’, 6’-
diamidino-2-phenylindole to stain nuclei blue and examined by
fluorescent microscopy. White arrows indicated centrosomes.
(C) After fluorescent staining with anti-centrosome antibodies, the
number of cells with more than two centrosomes was counted (at
least 400 cells counted) and compared between cell lines.Immunohistochemistry for centrosomes
Centrosome structures and count was estimated according
to the definition as previously described [17,20]. Briefly,
endogenous peroxidase was quenched with 3% H2O2,
slides were blocked with 5% normal goat serum for
15 min, followed by incubation with mouse anti-human
g-tubulin antibody to identify centrosomes (200 μg/mL;
Santa Cruz, Inc.) for 1h at room temperature. Centrosome
structures were identified and enumerated in four ran-
domly selected fields of stained tissue sections using Zeiss
axioplan microscope. Cells with more than two centro-
somes per cell were counted in 200 consecutive cells and
an average calculated among the nine samples in each
group. The investigator counting the number of centro-
somes was blinded to WDR62 expression.Statistical analysis
Statistical analyses were performed using SPSS 13.0 soft-
ware (SPSS, Chicago, IL, USA). Kruskall–Wallis and
Mann–Whitney U nonparametric tests were utilized to
compare differences between WDR62 expression levels.
The correlation between WDR62 expression and clinico-
pathological features of OC patients was analysed by the
χ2 test or Fisher’s exact test. All the tests were two-sided
and p < 0.05 was considered as statistically significant.
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WDR62 expression and centrosome amplification in
ovarian cell lines
Western blot analysis was conducted on multiple OC cell
lines for WDR62 protein expression. All cancer cell lines
expressed high levels of WDR62 protein (Figure 1A), and
expression levels in OC cells (SKOV3, SW626, Caov-3,
OVCAR3, and OV-90) were significantly higher compared
with A2780 cells, which are P53 wild type cell lines. Since
WDR62 overexpression is associated with centrosome
amplification, these six cell lines were then examined for
supernumerary centrosomes. After immunofluorescent
staining (Figure 1B), the number of visible centrosomes
was counted, and the percentage of cells with more than
two centrosomes per cell was calculated (Figure 1C). Cell
lines were considered aneuploid if >5% of cells exhibit
more than two centrosomes per cell [4], and all ovarian
cancer cell lines exhibited supernumerary centrosomes.
Interestingly, the WDR62 expression and average centro-
some count of high grade ovarian cancer cells (OV-90)
were significantly higher than others.
Expression of WDR62 protein in ovarian cancer tissues
Six normal ovarian epithelium samples had shown nega-
tively IHC staining (Figure 2A). As shown in Figure 2B & C.
Generally, most high-grade OC showed nuclear staining
or only had extremely faint cytoplasmic expression. The
low-grade carcinomas had significantly more sections thatFigure 2 Immunohistochemistry for WDR62. Six normal ovaries (A) and
Degree of staining in low-grade and high-grade ovarian carcinoma are sho
or ×400 (high power).expressed strong nuclear staining than high-grade carcin-
omas. WDR62 protein overexpression is associated with
clinical features. An analysis of clinical factors and their
association with WDR62 expression was conducted
(Table 1). WDR62 expression was significantly different
when comparing early stage (I-II) and advanced (III-IV)
patients. The upregulation of WDR62 was validated by
western blot analyses. Protein extracted from high-grade
OC showed stronger evidence of WDR62 expression
(Figure 3).
WDR62 overexpression is associated with centrosome
amplification in OC
Centrosome amplification has been observed in OC
cells in which WDR62 overexpression (Figure 1B & C),
in the OC tissues with the low and high WDR62 expres-
sion (as in Figure 4A & B, respectively). Centrosome
amplification was defined as more than two centro-
somes in any one cell. In patients with the highest
WDR62 expression, the mean number of cells with
centrosomal amplification was 56.2% +/− 29.5%, signifi-
cantly higher than in patients with low expression
(11.9%, SD 4.7%; p = 0.012).
Discussion
Although WDR62 expression has been detected in human
tissues, such as heart, skeletal muscles, testes and neuronal
precursors in brain [14,15], its expression pattern and85 epithelial ovarian cancer (EOC) specimens were stained for WDR62.
wn (B and C, respectively). Original magnification, ×100 (low power)
Figure 3 Western blot examination of WDR62 protein in low-
grade and high-grade ovarian carcinoma.
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novel findings from this study are that WDR62 is
overexpressed in most of the epithelial ovarian cancer cell
lines and tumors especially in high-grade carcinoma of the
ovary which was associated with high frequency of p53
mutation [21-23].
In this study, we have shown that the higher WDR62 ex-
pression have concurrent significantly higher centrosomeFigure 4 Centrosome amplification in ovarian cancer samples.
The nine patient samples with the highest WDR62 expression and
the nine samples with the lowest expression were subjected to
immunohistochemistry against g-tubulin to identify centrosome.
Samples with high expression (A), had a significantly higher
percentage of cells with supernumerary centrosome than those with
lower expression (B). The percentage of cells with more than two
centrosomes seen in 200 consecutive cells in each group, with the
mean, 25th and 75th quartiles, and minimum and maximum values.
Original magnification, ×400 (high power).count in OC cell lines and tissues. WDR62 overexpression
may contribute to carcinogenesis by centrosome amplifi-
cation, leading to abnormal mitosis. Our results show that
WDR62 overexpression was significantly higher in high-
grade carcinoma than in other types of ovarian cancer.
Centrosome amplification is a mechanism that can lead to
chromosomal instability, which in turn, results in further
mutations. Therefore, WDR62 overexpression may result
in genetic instability that may not only predispose to the
rapid development of epithelial ovarian cancer, but also
predispose cells to further genetic alterations and hetero-
geneity with evolving resistance to therapy. Consistent
with this, increased Aurora-A kinase expression was
strongly related to centrosome amplification and poor
prognosis of OC. Aurora-A has also been shown to inter-
act with p53 and reduce its effectiveness as a protector of
genome integrity [9,24]. We have described a direct correl-
ation between WDR62 expression and centrosome ampli-
fication, which provides a clear pathway towards the
development of aneuploidy. WDR62 maybe an effecter of
centrosome amplification in OC. We propose that
WDR62 overexpression is an important biomarker for the
diagnosis and possibly associated with tumorigenesis of
ovarian carcinoma.
Conclusion
Our present study suggests that WDR62 overexpression is
an important molecular change specifically related to OC
with centrosome amplification, which seems to play a role
in both tumor initiation and progression. In addition,
WDR62 overexpression can be a potential biomarker for
the detection and differentiation grade of OC. Examin-
ation of WDR62 targeting agents in OC is warranted.
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